8-2-1　ⓔ文献

  1. Randle PJ, Garland PB, et al: The glucose fatty–acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet, 1963; 1: 785–789.

  2. Hue L, Taegtmeyer H: The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab, 2009; 297: E578–591.

  3. Kolwicz SC Jr: An "exercise" in cardiac metabolism. Front Cardiovasc Med, 2018; 5: 66.

  4. Gibb AA, Hill B: Metabolic coordination of physiological and pathological cardiac remodeling. Circ Res, 2018; 123: 107–128.

  5. Noordali H, Loudon BL, et al: Cardiac metabolism–a promising therapeutic target for heart failure. Pharmacol Ther, 2018; 182: 95–114.

  6. Neubauer SN: The failing heart–an engine out of fuel. Engl J Med, 2007; 356: 1140–1151.

  7. Neubauer S: Myocardial phosphocreatine–to–ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation, 1997; 96: 2190–2196.

  8. Phan TT: Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol, 2009; 54: 402–409.

  9. Kolwicz SC Jr: Cardiac–specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure–overload hypertrophy. Circ Res, 2012; 111: 728–738.

  10. Bedi KC Jr: Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation, 2016; 133: 706–716.

  11. Makrecka–Kuka M: Altered mitochondrial metabolism in the insulin–resistant heart. Acta Physiol (Oxf), 2019: e13430.

  12. Rubler S: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol, 1972; 30: 595–602.

  13. Mjos OD: Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest, 1971; 50: 1386–1389.

  14. Hatori M: Time–restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high–fat diet. Cell Metab, 2012; 15: 848–860.

  15. Hafstad AD: High–and moderate–intensity training normalizes ventricular function and mechanoenergetics in mice with diet-induced obesity. Diabetes, 2013; 62: 2287–2294.

  16. Zinman B, Wanner C, et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373: 2117–2128.

  17. Neal B, Perkovic V, et al: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017; 377: 644–657.

  18. Wiviott SD, Raz I, et al: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2019; 380: 347–357.